The AMJEVITA impact: Innovative U.S. biosimilar pricing models
Clarivate
JULY 5, 2023
The month of July could see seven FDA-approved adalimumab biosimilars launch in the United States, an unprecedented situation for a market that has been relatively slow to embrace biosimilars. The Biosimilars Forum has hailed 2022 as a watershed year that could create a more competitive U.S. from 91% in 2023 to 36% by 2031.
Let's personalize your content